Use of the osteoprotegrin gene to regulate levels of OPG.

摘要

The use of an Osteprotegerin (OPG) encoding nucleic acid molecule in the preparation of a medicament for regulating OPG levels. The OPG medicament is also useful in treating bone disorders such as osteoporosis, Paget's disease of bone, hypercalcemia hyperparathyrodism, steroid induced osteopenia, bone loss associated with rheumatoid arthritis, osteomylitis, osteolytic metastasis and periodontal bone loss. The composition further contains a substance selected from the group consisting of bone morphogenic proteins BMP-1 through BMP-12, TGF-b family members, IL-1 inhibitors, TNF-a, inhibitors, parathyroid hormone related protein, E series prostaglandins, bisphosphonates and bone-enhancing minerals.